Internal Medicine, Cardiovascular Disease · Wichita, KS
NPI
1003879974
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
5
Medicare group memberships
Hospitals
5
Hospital affiliations
9350 E 35th St N, Ste 101
Wichita, KS, 67226
Phone (316) 265-1308
Groups this clinician bills Medicare through
Medicare paid, 2024
$606K
9,132 services
Medicare patients, 2024
2,175
Average age 77
Drug cost, 2024
$1.9M
16,412 prescriptions
Company payments, 2025
$624
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Layne M Reusser was code 99213 (office e&m - established), 1,279 times for 1,080 patients. In total Layne M Reusser billed 9,132 services in 71 codes, and Medicare paid $606K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,279 | 1,080 | $60.83 | $78K |
| 99214 Office E&M - Established | Office | 932 | 753 | $86.51 | $81K |
| 93296 External Electrocardiographic Monitoring | Office | 865 | 352 | $13.38 | $12K |
| 93294 External Electrocardiographic Monitoring | Office | 847 | 344 | $19.07 | $16K |
| 93306 Echocardiography (TTE/TEE) | Office | 708 | 681 | $120.51 | $85K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 676 | 169 | $5.57 | $3,762 |
| A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 592 | 296 | $86.60 | $51K |
| 99232 Hospital E&M - Subsequent | Facility | 308 | 174 | $57.85 | $18K |
| 93015 Electrocardiogram | Office | 300 | 300 | $45.29 | $14K |
| 78452 Myocardial Perfusion Scan | Office | 298 | 298 | $286.22 | $85K |
| 93280 External Electrocardiographic Monitoring | Office | 254 | 227 | $40.33 | $10K |
| 99231 Hospital E&M - Subsequent | Facility | 229 | 141 | $36.26 | $8,305 |
| 99152 Anesthesia | Facility | 209 | 195 | $8.81 | $1,841 |
| 93000 Electrocardiogram | Office | 191 | 181 | $9.64 | $1,842 |
| 99204 Office E&M - New | Office | 178 | 178 | $107.55 | $19K |
By year: 2022 $651K for 8,916 services; 2023 $699K for 9,436 services; 2024 $606K for 9,132 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 88 | 24 | $8.65 | $761 |
Medicare prescription drug claims, 2024
In 2024, the drug Layne M Reusser prescribed most often to Medicare patients was Metoprolol Succinate, with 1,266 prescriptions and refills. In total Layne M Reusser wrote 16,412 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metoprolol Succinate Generic | 1,266 | 2,920 | 332 | $13K |
| Amlodipine Besylate Generic | 1,246 | 2,951 | 321 | $5,297 |
| Atorvastatin Calcium Generic | 1,052 | 2,625 | 262 | $7,815 |
| Eliquis Apixaban | 908 | 1,277 | 145 | $749K |
| Metoprolol Tartrate Generic | 825 | 1,873 | 209 | $3,827 |
| Digoxin Generic | 704 | 1,400 | 157 | $15K |
| Clopidogrel Clopidogrel Bisulfate | 695 | 1,590 | 170 | $4,508 |
| Xarelto Rivaroxaban | 628 | 1,085 | 113 | $589K |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | 543 | 1,169 | 149 | $13K |
| Verapamil Er Verapamil Hcl | 526 | 1,076 | 130 | $12K |
| Losartan Potassium Generic | 517 | 1,238 | 139 | $4,740 |
| Lisinopril Generic | 462 | 1,171 | 136 | $2,548 |
| Potassium Chloride Generic | 425 | 939 | 117 | $5,507 |
| Furosemide Generic | 409 | 889 | 116 | $1,264 |
| Carvedilol Generic | 402 | 928 | 102 | $1,754 |
Brand drugs: - claims; generic drugs: 14,216 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Layne M Reusser $624 ($624 in general payments such as food, travel and fees) from 6 companies. The largest payer was Medtronic, Inc. with $362.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.